[Ga-68]-DOTATATE Injection (“[Ga-68]-DOTATATE”), used in combination with positron emission tomography (PET), is being studied as an imaging biomarker for neuroendocrine tumors (NETs). NETs are an uncommon and diverse group of cancers that arise from neuroendocrine cells, most often in the gastroenteropancreatic tract or lungs. [Ga-68]-DOTATATE is a radiolabelled somatostatin analogue with high and specific affinity for somatostatin receptor subtype 2 (SSTR2); the characteristic overexpression of SSTRs in NETs forms the basis for PET imaging with [Ga-68]-DOTATATE.

[Ga-68]-DOTATATE may have utility in the following NET applications: confirming diagnosis, locating metastatic lesions or primary occult tumours, and determining SSTR status.


Albanus RR, Verburg FA, Behrendt FF et al. Clinical value of 68Ga-DOTA-TATE PET-CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumors (NET) Eur J Radiol. 2015; 84(10): 1866-1872.

http://www.ncbi.nlm.nih.gov/pubmed 26152870

Haug AR, Cindea-Drimus R, Auernhammer CJ et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med. 2012; 53(11):1686-92.


Kunikowska J, Pawlak D, Kolasa A et al. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin Nucl Med. 2014; 39(10):855-61.



These references are provided for informational purposes only and do not represent an endorsement for any particular clinical use. 

Investigational Product Use Only

The safety and efficacy of [Ga-68]-DOTATATE Injection have not been fully established and it has not been approved by Health Canada as a commercial product for medicinal use. It is an investigational drug product and can only be used under an approved clinical trial application (CTA). Please contact the CPDC if you require further information.